Tecentriq 1200mg Injection

Most side effects of Tecentriq 1200mg Injection do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Some common side effects include:

• Fever
• Loss of appetite
• Urinary tract infection
• Pain in the joints, muscles, and bones
• Headache
• Hair loss
• Numbness in hands and feet
• Sensitivity to sun
• Constipation
• Low oxygen level
• High blood sugar
• Pain in stomach, mouth, and throat
  

Tecentriq 1200mg Injection is a prescription-based anticancer drug. It is advised to take this injection after consulting your healthcare expert. Atezolizumab medicine should be given intravenously by an experienced nurse or doctor.

Please do not self-administer. Doctor determine the dosage and duration of the drug as per the stage & type of cancer, and overall health condition of the patient.

• ​Tecentriq 1200mg Injection   is an anticancer medicine with active ingredient Atezolizumab which is a monoclonal antibody.
• It works by blocking the interaction between PD-L1 and PD-1 which blocks the PD-1/PD-L1 pathway and stimulates the immune response to fight against the cancer cells.
• This drug restores the anti-tumor T cell activity which attacks the cancer cells. This, as a result, stops the uncontrollable growth and spreading of cancerous cells in the lungs.​
  

1. Markham, A. (2016). Atezolizumab: first global approval. Drugs, 76(12), 1227-1232 - https://pubmed.ncbi.nlm.nih.gov/27412122/
2. Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Baranda, L. H., Liu, S., ... & Felip, E. (2022). 61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC). Immuno-Oncology and Technology, 16 - https://pubmed.ncbi.nlm.nih.gov/37268157/
3. Chiang, A. C., Sequist, L. V. D., Gilbert, J., Conkling, P., Thompson, D., Marcoux, J. P., ... & Gordon, M. S. (2020). Clinical activity and safety of atezolizumab in a phase 1 study of patients with relapsed/refractory small-cell lung cancer. Clinical Lung Cancer, 21(5), 455-463\ -  https://pubmed.ncbi.nlm.nih.gov/32586767/
4. Xie, J., Mao, Q. Y., Chen, J. H., Shi, H. J., Zhan, P. Q., & Wang, H. F. (2025). Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a systematic review and meta-analysis. World Journal of Surgical Oncology, 23(1), 133 - https://pmc.ncbi.nlm.nih.gov/articles/PMC11983893/
5. Adams, S., Diamond, J. R., Hamilton, E., Pohlmann, P. R., Tolaney, S. M., Chang, C. W., ... & Powderly, J. (2019). Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA oncology, 5(3), 334-342 - https://pubmed.ncbi.nlm.nih.gov/30347025/